Role of public and press key to ensuring funding u-turn on Kadcyla, says Roche's Deborah Lancaster

27 April 2017

In a claim that will make patient groups, PR companies and communication teams at pharma companies sit up and listen, the market access director for Swiss pharma giant Roche (SIX: ROG) has said that pressure from the public and media was key to an innovative cancer drug being made available for Scottish women on the National Health Service (NHS).

Health technology assessment (HTA) bodies are often tied to strict cost-effectiveness thresholds such as the quality adjusted life years (QALYs) measure employed by the National Institute for Health and Care Excellence (NICE) over the border in England.

"With the UK being such an R&D leader, it doesn’t sit right that patients can’t have access to the benefits accrued by the research"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK